Evidence map›Paper›PMID 40861228›Full record

SynthesisFrontiers in medicine2025

The efficacy and safety of androgen analog oxandrolone in improving clinical outcomes in burn patients: a systematic review and meta-analysis of randomized controlled trials.

Jiaqi Lou, Ziyi Xiang, Xiaoyu Zhu, Jingyao Song, Neng Huang, Jiliang Li, Guoying Jin, Youfen Fan, Shengyong Cui

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiaqi Lou *Burn Department, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Ziyi Xiang *Health Science Center, Ningbo University, Ningbo, Zhejiang, China.
Xiaoyu Zhu *Faculty of Medicine, Institute of Pathology, University of Bonn, Bonn, Germany.
Jingyao SongSchool of Mental Health, Wenzhou Medical University, Whenzhou, China.
Neng HuangBurn Department, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Jiliang LiBurn Department, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Guoying JinBurn Department, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Youfen FanBurn Department, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Shengyong CuiBurn Department, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This latest systematic review and meta-analysis aim to examine efficacy and safety of androgen analog oxandrolone in burn patients. Methods: Relevant articles were retrieved from Pubmed, Embase, Cochrane, Web of science, International Clinical Trials Registry Platform, China National Knowledge Infrastructure, VIP Database for Chinese Technical Periodicals, Wanfang database and China Biology Medicine disc. The output measures were the weight loss in catabolic phase, weight gain in recovery phase, lean body mass in recovery phas, operation times, healing time of donor area, length of hospital stay/total body surface area burned (LOS/TBSA%), length of hospital stay (LOS), side effects, infection and mortality. Data were pooled and expressed as relative risk (RR) and standardized mean difference (SMD) with a 95% confidence interval (CI). Results: 19 studies were included in this systematic review and meta-analysis, with 779 patients who received oxandrolone (treatment group) and 1,227 patients who received standard care or placebo (control group). The pooled data from all included studies demonstrated that the treatment group has significantly reduced weight loss in catabolic phase (SMD = 1.86; 95% CI: -0.13-3.84; Conclusion: Our meta-analysis showed that oxandrolone supplements are beneficial for burn patients as they significantly reduce the weight loss in catabolic phase, operation times, LOS/TBSA%, LOS, mortality and increase weight gain and lean body mass in recovery phase. However, this intervention has minimal impact on healing time of donor area, side effects and infection.

Indexed as

androgen analogburn patientsmeta analysismortalityoxandrolone

Identifiers

PMID40861228
PMCPMC12370634

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.